Long‐Term Glycemic and Metabolic Profiles Observed During Imeglimin Therapy in Japanese Patients With Type 2 Diabetes Mellitus
Endocrinology, Diabetes & Metabolism · 2026-07 · 9 (4)
DOI: 10.1002/edm2.70263 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 06.07.2026. Verfasst von Yohei Fujita und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Osaka General Medical Center, Osaka, Osaka, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Blood Glucose, Hypoglycemic Agents. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims/Introduction Imeglimin is a first‐in‐class oral antidiabetic agent that improves glycemia through dual actions on insulin secretion and sensitivity. However, real‐world data on its long‐term metabolic effects, particularly on endogenous insulin secretion, remain limited. We aimed to evaluate 12‐month longitudinal changes in glycemic indices, an insulin secretion index, and treatment intensity during imeglimin therapy in routine clinical practice. Materials and Methods This retrospective observational study included 73 Japanese patients with type 2 diabetes mellitus who continued imeglimin therapy for approximately 12 months. Hemoglobin A1c (HbA1c) and glycated albumin (GA) were assessed at baseline and follow‐up. Fasting plasma glucose and C‐peptide levels obtained between 10 and 14 months after initiation were used to calculate the fasting C‐peptide index (fCPI). Overall glucose‐lowering treatment intensity was quantified using the medication effect score (MES).
Results
HbA1c significantly decreased from 8.55% ± 1.38% to 7.67% ± 0.99% over 12 months ( p < 0.0001). GA also declined from the early phase after initiation, whereas the GA/HbA1c ratio showed only transient change without sustained differences. The fCPI increased from 1.14 [0.65–1.84] to 1.21 [0.79–2.01] ( n = 69, p = 0.003), and an early increase was observed within 1–2 months. Despite frequent adjustments to background therapies, treatment intensity as assessed by MES did not change significantly.
Conclusions
In a real‐world setting, long‐term imeglimin therapy was associated with sustained glycemic improvement and early as well as sustained numerical changes in an insulin secretion index without an increase in overall treatment intensity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diabetes and Endocrinology, Osaka General Medical Center, Osaka, Osaka, Japan.
ORCID-Profile: Yohei Fujita, Masahiro Hatazaki
Zitieren
APA
Fujita, Y., Suganami, S., Morita, Y., Matsui, T., Hata, M., & Hatazaki, M. (2026). Long‐Term Glycemic and Metabolic Profiles Observed During Imeglimin Therapy in Japanese Patients With Type 2 Diabetes Mellitus. Endocrinology, Diabetes & Metabolism, 9(4). https://doi.org/10.1002/edm2.70263
Vancouver
Fujita Y, Suganami S, Morita Y, Matsui T, Hata M, Hatazaki M. Long‐Term Glycemic and Metabolic Profiles Observed During Imeglimin Therapy in Japanese Patients With Type 2 Diabetes Mellitus. Endocrinology, Diabetes & Metabolism. 2026;9(4). doi:10.1002/edm2.70263
BibTeX
@article{Fujita2026,
author = {Fujita, Yohei and Suganami, Shuji and Morita, Yuka and Matsui, Toshio and Hata, Masahisa and Hatazaki, Masahiro},
title = {Long‐Term Glycemic and Metabolic Profiles Observed During Imeglimin Therapy in Japanese Patients With Type 2 Diabetes Mellitus},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2026},
volume = {9},
number = {4},
doi = {10.1002/edm2.70263}
}
EUVIMED